Global Beta-lactam and Beta-lactamase Inhibitors Market to Touch USD 31780 Mn by 2027 as per the Latest Research

The global Beta-lactam and Beta-lactamase Inhibitors market was valued at US$ 23720 million in 2020 and is expected to reach US$ 31780 million by the end of 2027, growing at a CAGR of 1.9% during 2021-2027.

β-Lactams are the most widely used class of antibiotics. Since the discovery of benzylpenicillin in the 1920s, thousands of new penicillin derivatives and related β-lactam classes of cephalosporins, cephamycins, monobactams, and carbapenems have been discovered. Each new class of b-lactam has been developed either to increase the spectrum of activity to include additional bacterial species or to address specific resistance mechanisms that have arisen in the targeted bacterial population. Resistance to β-lactams is primarily because of bacterially produced β-lactamase enzymes that hydrolyze the β-lactam ring, thereby inactivating the drug. The newest effort to circumvent resistance is the development of novel broad-spectrum β-lactamase inhibitors that work against many problematic β-lactamases, including cephalosporinases and serine-based carbapenemases, which severely limit therapeutic options.

In the global market, the core manufacturers of Beta-lactam and Beta-lactamase Inhibitors include Pfizer and Novartis (Sandoz) etc, and the top 2 manufacturers account for about 10% of the market share. The market include Asia Pacific, Europe and North America, with a share of 33%, 32% and 28%. cephalosporins accounted for 28% and penicillins accounted for 17%. The product is mainly used in intravenous and oral, with a share of 65% and 35%.

Global Beta-lactam and Beta-lactamase Inhibitors Market: Drivers and Restrains

The research report has incorporated the analysis of different factors that augment the market’s growth. It constitutes trends, restraints, and drivers that transform the market in either a positive or negative manner. This section also provides the scope of different segments and applications that can potentially influence the market in the future. The detailed information is based on current trends and historic milestones. This section also provides an analysis of the volume of production about the global market and about each type from 2016 to 2027. This section mentions the volume of production by region from 2016 to 2027. Pricing analysis is included in the report according to each type from the year 2016 to 2027, manufacturer from 2016 to 2021, region from 2016 to 2021, and global price from 2016 to 2027.

A thorough evaluation of the restrains included in the report portrays the contrast to drivers and gives room for strategic planning. Factors that overshadow the market growth are pivotal as they can be understood to devise different bends for getting hold of the lucrative opportunities that are present in the ever-growing market. Additionally, insights into market expert’s opinions have been taken to understand the market better.

Global Beta-lactam and Beta-lactamase Inhibitors Market: Segment Analysis

The research report includes specific segments by region (country), by manufacturers, by Type and by Application. Each type provides information about the production during the forecast period of 2016 to 2027.

Key Companies profiled in this report are Pfizer, Novartis (Sandoz), Teva, Merck, Abbvie (Allergan), Sumitomo Dainippon, Hikma, Aurobindo Pharma, Wockhardt, Lupin Limited, Fresenius Kabi, B. Braun, Usantibiotics, Qilu Pharmaceutical, Acs Dobfar, Nichi-Iko (Sagent), Antibiotice and more in terms of market share by sales, revenue, average pricing, product type, margins, recent developments etc.

Find more details at:

Segment by Type

  • Penicillins
  • Cephalosporins
  • Carbapenems
  • Monobactams
  • Combinations

Segment by Application

  • Oral
  • Intravenous

Table of Content:

1 Beta-lactam and Beta-lactamase Inhibitors Market Overview

2 Beta-lactam and Beta-lactamase Inhibitors Market Competition by Manufacturers

3 Beta-lactam and Beta-lactamase Inhibitors Retrospective Market Scenario by Region

4 Global Beta-lactam and Beta-lactamase Inhibitors Historic Market Analysis by Type

5 Global Beta-lactam and Beta-lactamase Inhibitors Historic Market Analysis by Application

6 Key Companies Profiled

7 Beta-lactam and Beta-lactamase Inhibitors Manufacturing Cost Analysis

8 Marketing Channel, Distributors and Customers

9 Beta-lactam and Beta-lactamase Inhibitors Market Dynamics

10 Global Beta-lactam and Beta-lactamase Inhibitors Market Forecast

11 Research Finding and Conclusion

12 Methodology and Data Source

Media Contact

Company Name: The Market Reports

Contact Person: Shirish Gupta


Phone: +1-631-407-1315